(DEDHAM, MA) – Greater Boston Urology recently announced the official opening of its Women’s Health Center at 910 Washington Street in Dedham, Massachusetts. Dr. Angel Marie Johnson, a urogynecologist who completed her training at Massachusetts General Hospital/Harvard Medical School, will be heading up the Center.

(Dedham, MA) – Earlier this month, the U.S. Preventive Services Task Force (USPSTF) released its prostate cancer screening draft recommendations for public comment. These latest recommendations show a shift in thinking.

(BOSTON, MA) – Greater Boston Urology is pleased to announce the opening of its newest location—”Destination Dedham”—in Dedham, Massachusetts. This location will serve as Greater Boston Urology’s main headquarters as well.

(Boston, MA) – In June 2016, The Journal of Urology published a consensus statement from the American Urological Association (AUA) and Society of Abdominal Radiology (SAR) regarding prostate magnetic resonance imaging (MRI)…

(BOSTON, MA) – Healthcare research company Castle Connolly Medical Ltd identified 245 outstanding physicians in Barnstable, Norfolk, and Plymouth counties. Of the four urologists named, three are from Greater Boston Urology:

(BOSTON, MA) – Greater Boston Urology announced today that two of its doctors were the first in Massachusetts to perform a new, non-invasive treatment for prostate cancer known as High Intensity Focused Ultrasound or HIFU.

(BOSTON, MA) – Award-winning Greater Boston Urology (GBU) physician Dr. Michael J. Curran, M.D., will be speaking at the Sharon Men’s Club on Tuesday, February 9, 2016 at 9:00 AM at the Sharon Community Center to discuss the importance of optimal prostate health.

GBU’s own Dr. Keith Bleiler was featured on “The Point,” NPR’s Award-Winning Public Affairs Program on Thursday, January 21st.

(Boston, MA) Dr. Keith Bleiler of Greater Boston Urology (GBU) will be featured on NPR’s The Point with Mindy Todd on Thursday, January 21st at 9 AM to discuss the new U.S. Preventive Services Task Force (USPSTF), screening recommendations for both prostate and breast cancer and whether it is in the best interest of patients.